Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jan 29, 2013

Thermo, Barnett Institute Forge LC-MS Tech Alliance

  • Thermo Fisher Scientific and scientists at the Barnett Institute, Northeastern University, Boston, have entered a Technology Alliance Partnership agreement, with the goal of accelerating research in high-resolution accurate mass liquid chromatography-mass spectrometry (LC-MS) applications.

    This collaboration will include performing research and sharing samples and data that could lead to development of improved techniques, exchanging ideas and opinions about improving instrument and software performance, discourse about current technology issues, and publishing new methodologies and scientific advances.

    The alliance, with the Barnett Institute’s director, Barry Karger, and team, will focus on three research areas:

    • Comprehensive characterization of complex proteins
    • Ultra-trace analysis methodologies of proteomic samples
    • New LCMS-based methods for analysis of biosimilars

    “Academic research labs are tremendous sources of innovation, which is why we’re so pleased to collaborate with Northeastern scientists who have particular expertise in combining the strengths of separation science and high-resolution MS analysis of proteins,” said Iain Mylchreest, vp, R&D at Thermo Fisher.

    This wouldn't be the first time Thermo has partnered with scientists from a university. Back in July of 2010, they established a Biomarker Research Center in Tokyo, Japan, with Toshihide Nishimura, a professor at the Tokyo Medical University Hospital, and Gyorgy Marko-Varga, professor at the Tokyo Medical University Hospital and Lund University, Sweden, with a focus on biomarker discovery and quantification, disease mechanisms, therapeutic drug monitoring, and disease pathophysiology.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »